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Can an amino acid mixture alleviate
gastrointestinal symptoms in
neuroendocrine tumor patients?
Aman Chauhan1,2* , Satya Das3, Rachel Miller2, Laura Luque4, Samuel N. Cheuvront4, James Cloud5, Zach Tarter5,
Fariha Siddiqui5, Robert A. Ramirez6 and Lowell Anthony1,2
Abstract
Background: Neuroendocrine tumors, although relatively rare in incidence, are now the second most prevalent
gastrointestinal neoplasm owing to indolent disease biology. A small but significant sub-group of neuroendocrine
tumor patients suffer from diarrhea. This is usually secondary to carcinoid syndrome but can also be a result of
short gut syndrome, bile acid excess or iatrogenic etiologies. Recently, an amino acid based oral rehydration
solution (enterade® Advanced Oncology Formula) was found to have anti-diarrheal properties in preclinical models.
Methods: A retrospective chart review of all NET patients treated with enterade® AO was performed after IRB
approval.
Results: Ninety-eight NET patients who had received enterade® AO at our clinic from May 2017 through June 2019
were included. Patients (N = 49 of 98) with follow up data on bowel movements (BMs) were included for final
analysis. Eighty-four percent of patients (41/49) had fewer BMs after taking enterade® AO and 66% (27/41) reported
more than 50% reduction in BM frequency. The mean number of daily BMs was 6.6 (range, 3–20) at baseline before
initiation of therapy, while the mean number of BMs at 1 week time point post enterade® AO was 2.9 (range, 0–11).
Conclusions: Our retrospective observations are encouraging and support prospective validation with appropriate
controls in NET patients. This is first published report of the potential anti-diarrheal activity of enterade® AO in NET
patients.
Keywords: Neuroendocrine tumors, Amino acid oral rehydration solution, Diarrhea, Excess bowel movements
Background
Neuroendocrine tumors (NETs) are rare and unique slow
growing tumors that can originate from varied organ sites
[1]. The prevalence of NETs has increased in the United
States over 6-fold from 1973 to 2012, primarily due to im-
proved diagnostics for early-stage disease and potency of
systemic treatments leading to improved survival in the
metastatic setting [2, 3]. NETs are classified as non-
functional or functional tumors; non-functional tumors
do not secrete hormones, while functional, non-
pancreatic, NETs primarily secrete serotonin, resulting in
carcinoid syndrome [1]. Approximately 10–50% of pa-
tients with NETs will develop carcinoid syndrome [4–7]
and its associated symptoms of flushing and frequent,
often explosive, watery diarrhea (62–78%) [4, 5, 8]. Carcin-
oid syndrome diarrhea can be distressing with many pa-
tients reporting bowel movements (BM) ranging from two
to 30 or more per day [9]. Patients with NETs may also
have moderate to severe diarrhea due to other etiologies
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including toxicity from chemotherapy, radiation and se-
quelae of gastrointestinal surgery [10–17].
Diarrhea and BM frequency in functional NET pa-
tients is typically managed with somatostatin analogs
and telotristat ethyl (tryptophan hydroxylase inhibitor).
Over-the-counter anti-diarrheal medications are also
often utilized for breakthrough diarrhea. However, it is
not uncommon for NET patients to continue to have
persistent debilitating diarrhea despite treatment with
multimodal agents.
We examined the potential for enterade® Advanced
Oncology (AO) Formula to reduce BM frequency in
NET patients. Enterade® AO consists of a unique blend
of five amino acids (Valine, Aspartic Acid, Serine,
Threonine, Tyrosine) selected for their ability to restore
bowel absorption and integrity [18]. Enterade® AO add-
itionally contains electrolytes and flavors. Preclinical data
suggest that enterade® AO can restore enteral integrity
following radiation-induced gut damage in mice [15, 17,
19]. We previously reported our anecdotal experience
with enterade® AO in a cancer patient who noted signifi-
cant clinical improvement in gastrointestinal symptoms
[20]. Non-toxic and inexpensive enteral nutritional ther-
apies for decreasing diarrhea and BM frequency in NET
patients, regardless of cause, can significantly improve
patient quality of life and reduce patient and hospital
costs [20]. Because of these observations, we elected to
review our experience with enterade® AO in reducing




Retrospective chart review was conducted after appro-
priate University of Kentucky Institutional Review Board
(IRB) approval.
Objective and hypothesis
A retrospective chart review of all NET patients treated
with enterade® AO under supervision of a registered
dietitian in an oncology clinic setting was performed. All
NET patients managed at Markey Cancer Center are
screened for chronic diarrhea that is co-managed by
medical oncology and registered dietitians. Interventions
include pharmacologic and counseling measures focused
on diet and nutrition. Any patients experiencing 4 or
more stools were instructed to consume one 8 oz. bottle
of enterade® AO twice daily, 30 min before meals or 1 h
after meals for at least 1 week. Patients were provided a
one-week supply of samples (supported by Lockey Foun-
dation Philanthropic Grant to Markey NET Clinic). If
patients noted improvement in diarrhea, they were able
to continue enterade® AO by buying the product over
the counter. Most patients were followed up at 1 week
over the phone to determine the number of BMs per
day, and if the patient had any adverse side-effects from
enterade® AO. Those who had no follow up at 1 week or
were lost to follow up were not included in this analysis.
The clinical data were retrospectively reviewed with a
primary objective of evaluating change in BM frequency
from before the trial of enterade® AO suppression com-
pared to after. The hypothesis was that enterade® AO,
when combined with standard supportive care, would
improve small bowel absorption, leading to a reduction
in BM frequency.
Medical records were also reviewed to obtain demo-
graphic data, information on the tumor type and loca-
tion, histopathology, frequency of diarrhea, and use of
somatostatin analogs.
Statistical analysis
Data were analyzed using descriptive statistics to gener-
ate means and ranges. Robust linear regression was used
to estimate the reduction in BM frequency afforded by
use of enterade® AO as a function of initial severity of
diarrhea. All statistical analyses were performed using
Prism GraphPad, version 8.0.
Results
Patient characteristics
We identified 98 NET patients who had received enter-
ade® AO at our clinic from May 2017 through June
2019. Patients (N = 49 of 98) with follow up data on
BMs were included for final analysis. The average age
was 61 years with a range of 33 to 84 years. Thirty-seven
(75%) patients possessed gastroenteropancreatic NETs, 8
possessed bronchial NETs, 1 possessed a gynecological
NET, and 3 possessed NETs of unknown primary origin.
Twenty-eight patients (57%) had a history of prior bowel
resection either for primary NET resection or debulking.
Twenty-eight patients (57%) were on somatostatin ana-
logs at the time of initiation of enterade® AO.
Antidiarrheal efficacy of enterade® AO
Eighty-four percent of patients (41/49) had fewer BMs
after taking enterade® AO and 66% (27/41) reported more
than 50% reduction in BM frequency. The mean number
of daily BMs was 6.6 (range, 3–20) at baseline before initi-
ation of therapy, while the mean number of BMs at day 7
after starting enterade® AO was 2.9 (range, 0–11).
The average time to improvement was 4.3 days. Five
patients had a marked decrease in BMs during the study
and their diarrhea completely resolved (zero diarrheal
BMs) by the end of the study. One patient reported the
side effect of constipation. There were no other adverse
reactions reported. Figure 1 Illustrates the reduction in
daily BM frequency for individual NET patients after
using enterade for at least 1-week. Data are sorted and
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ordered from largest to smallest benefits to illustrate the
effect magnitude and individual variability for n = 49
patients.
Discussion
The principal finding from this retrospective chart re-
view of NET patients experiencing life-limiting BM fre-
quency was that consumption of enterade® AO resulted
in a reduction in diarrhea, and that patients experiencing
the most severe number of BMs appeared to derive the
most benefit.
Traditionally, diarrhea in NET patients is managed
with somatostatin analogs, anti-motility agents, and opi-
oids. Nevertheless, some patients can continue to have
persistent debilitating diarrhea despite the utilization of
multi-modal agents. There are limited treatment options
for controlling diarrhea in this population, especially for
patients with severe, uncontrollable diarrhea. Somato-
statin analogs are reported to be 65–84% effective in de-
creasing the frequency of BMs [21]. However, it is
common for patients to become refractory to somato-
statin analogs. Telotristat ethyl, the first and only drug
approved by the United States Food and Drug Adminis-
tration for carcinoid syndrome diarrhea refractory to
somatostatin analogs, reduced diarrhea in 44% of NET
patients [22]. While telotristat is a significant advance
for carcinoid NET patients with diarrhea, there are still
NET patients with both functional syndrome as well as
non-syndromic diarrhea which can further benefit from
optimization of anti-diarrheal strategies.
Enterade® is a proprietary blend of five amino acids
(threonine, valine, serine, tyrosine, tryptophan) that
acutely restores water and electrolyte losses by facilitat-
ing intestinal sodium and water transport with similar
stoichiometry to glucose [23], but without stimulating
chloride secretion like glucose [24] Used prophylactically
and chronically as a treatment, enterade modulates in-
testinal transmembrane proteins to promote intestino-
trophic villus regrowth, increase sodium and water
absorption, decrease chloride and bicarbonate secretion,
and reduce intestinal paracellular permeability [24]
(Fig. 2). The benefits of enterade have been demon-
strated by improvements in body weight maintenance
and survival in mice with radiation enteritis and im-
proved diarrhea outcomes in oncology patients suffering
from toxic gut syndrome [24]. The potential benefits of
a non-toxic and inexpensive enteral nutrition therapy
like enterade® AO for effectively treating diarrhea in
NET patients looks promising and should be explored
further in a prospective study. Limitations of our current
study include lack of control group and a heterogenous
patient population, lack of designated follow up and lack
of a uniform outcome measurement. As mentioned pre-
viously, diarrhea in NET patients can be due to carcin-
oid syndrome, short gut syndrome, bacterial overgrowth,
bile acid colitis, steatorrhea etc. Our study was not con-
trolled for potential confounders and did not consider
the effect of supportive care medications in addition to
enterade® AO. Furthermore, 50% of patients in the initial
cohort did not have adequate follow up. It is possible
that these patients derived less benefit from enterade®
AO, and this loss to follow up introduced selection bias.
Also, as the post-treatment BM frequency assessment
was carried out approximately at 1 week, some potential
heterogeneity could have been observed around time of
outcome assessment. Despite these limitations, our early
clinical observation suggests potential anti-diarrheal ac-
tivity of enterade® AO and warrants validation of the
product in a well-controlled prospective clinical trial.
Our findings support further investigations of enter-
ade® AO for diarrhea mitigation in NET patients. This is
not entirely surprising as the enterade® AO mechanisms
of action include hyper-absorptive, anti-secretory, barrier
tightening, and villi proliferation effects within intestinal
epithelia [15, 17, 19] which directly combat many of the
pathophysiological effects of disease and treatment (radi-
ation and chemotherapy) [25, 26] (Fig. 2). Although the
placebo effect and biased reporting of favorable out-
comes cannot be ruled out as factors which influenced
outcomes in our analysis, the clinical outcomes observed
are promising and consistent with rigorous pre-clinical
anti-diarrheal data; these findings warrant further affirm-
ing prospective research.
Conclusion
Eighty-four percent (41/49) of NET patients reported
BM reduction with enterade® AO while 66% (27/41) re-
ported more than 50% reduction in BM frequency. In
conclusion, our retrospective observations are
Fig. 1 Plot of reduction in daily bowel movement frequency after
use of enterade for 1-week for n = 49 patients. Data are sorted and
ordered from largest to smallest benefits to illustrate the effect
magnitude and individual variability. Source: Author
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encouraging and support prospective validation in NET
patients. This is first published report of potential anti-
diarrheal activity of enterade® AO in NET patients.
There are two ongoing prospective phase 2 studies
(NCT02919670, NCT03722511) which are currently
evaluating the ability of enterade® AO to reduce BM fre-
quency and relieve gastrointestinal symptoms in this
population.
Abbreviations
AO: Advanced Oncology; BM: Bowel movement; NET: Neuroendocrine tumor
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